| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Delta 9 Cannabis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.01 |
| 52 Week High | CA$0.078 |
| 52 Week Low | CA$0.007 |
| Beta | 1.34 |
| 11 Month Change | -33.33% |
| 3 Month Change | -70.41% |
| 1 Year Change | n/a |
| 33 Year Change | -96.69% |
| 5 Year Change | -98.68% |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| V5D1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 42.9% | -1.3% | 0.9% |
| 1Y | n/a | -14.6% | 4.2% |
Return vs Industry: Insufficient data to determine how V5D1 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how V5D1 performed against the German Market.
Price Volatility
| V5D1 volatility | |
|---|---|
| V5D1 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: V5D1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine V5D1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 320 | John Arbuthnot | www.delta9.ca |
Delta 9 Cannabis Inc., together with its subsidiaries, operates as an integrated cannabis company. The company engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis products. Its products include dried cannabis flowers, pre-rolls, and dried sift cannabis, as well as oils, and extracted and derivative products.
Delta 9 Cannabis Inc. Fundamentals Summary
| V5D1 fundamental statistics | |
|---|---|
| Market cap | €3.43m |
| Earnings (TTM) | -€13.37m |
| Revenue (TTM) | €48.21m |
0.1x
P/S Ratio-0.3x
P/E RatioIs V5D1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V5D1 income statement (TTM) | |
|---|---|
| Revenue | CA$70.65m |
| Cost of Revenue | CA$58.10m |
| Gross Profit | CA$12.55m |
| Other Expenses | CA$32.15m |
| Earnings | -CA$19.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 17.77% |
| Net Profit Margin | -27.74% |
| Debt/Equity Ratio | -447.3% |
How did V5D1 perform over the long term?
See historical performance and comparison